“If your actions inspire others to dream more, learn more, do more and become more, you are a leader.”
—John Quincy Adams

AIT’s management team leads by example. They bring experience and passion and inspire us to excel.

Our team has extensive scientific knowledge and capabilities to lead us toward our goal to provide safe and effective nitric oxide therapies to treat patients worldwide.

Amir Avniel

Mr. Amir Avniel

Co-Founder, Chief Executive Officer and Director

Mr. Amir Avniel co-founded AIT in 2011 and became a director at that time.

Mr. Avniel has over 12 years of management experience in product development and product marketing, leading large teams from diverse backgrounds and industries to operational excellence. Mr. Avniel served as an executive on the Monsanto Israel business team and prior its purchase by Monsanto, Mr. Amir served as the President and Chief Executive Officer of Rosetta Green Ltd.
Mr. Avniel served as president and Chief Executive Officer of Rosetta Genomics (Nasdaq: ROSG). Under Amir’s leadership Rosetta Genomics went public in a NASDAQ IPO

Yossi Av-Gay

Prof. Yossef Av-Gay

Co-Founder and Chief Scientific Officer

Professor Yossef Av-Gay co-founded and became a director of AIT in 2011. He became chief scientific officer in 2012 and was appointed AIT’s chairman from 2014 to 2015.

He is engaged in translational research of bacterial pathogens aimed at antimicrobial drug development. Since 1997, Prof. Av-Gay has been on the Faculty of Medicine Division of Infectious Diseases at the University of British Columbia, where he teaches microbiology.

He consults to several pharmaceutical and biotechnology companies and is a member of the scientific review panels of the Canadian Institute of Health Research (since 2010), the French Agence Nationale de la Rechereche (since 2008), Innovative Medicine Innovations, the U.S. National Institutes of Health (since 2010), the European Commission FP6, FP7 (since 2002), and Horizon 2020 (since 2014).

Prof. Av-Gay holds a Ph.D. in molecular microbiology, an M.Sc. in microbiology, and a B.Sc., in biology, all from Tel Aviv University.

David-Greenberg

Prof. David Greenberg

Co-Founder and Medical Director

Professor David Greenberg co-founded AIT in 2011.

Prof. Greenberg has almost 20 years of professional experience in the research and treatment of infectious diseases. Since 2005, he has served as a professor of pediatrics and infectious diseases and the principal consultant to the Infectious Disease Clinical Service (pediatric oncology), Division of Pediatrics, at Soroka Medical Center in Beer-Sheba, Israel. In June 2014, he was appointed director of Pediatric Infectious Disease Unit at Soroka University Medical Center.

In addition, he was a member of the WHO’s Pneumonia Vaccine Trial Investigators’ Group and is a board member of the Educational Committee of the European Society of Pediatric Infectious Diseases.

Prof. Greenberg is board certified in pediatrics and has obtained his M.D. from Ben-Gurion University of the Negev. He completed a fellowship in 1999 in pediatric infectious diseases at British Columbia Children’s Hospital in Vancouver, British Columbia, Canada.

Racheli Vizman

Ms. Racheli Vizman

Chief Operating Officer

Ms. Racheli Vizman has served as AIT’s COO since 2012.

Ms. Vizman has over nine years of management experience in the biotechnology and medical device industries. She has substantial experience providing oversight of quality operations and associated teams in the areas of biotechnology, medical devices, in vitro diagnostics, and combination product lines.

Ms. Vizman served as a director of regulatory affairs of SharpLight Technologies Ltd., an Israeli medical device company, from 2011 through 2012. Prior to that, she was the senior director of regulatory affairs and quality assurance of at Rosetta Genomics (Nasdaq: ROSG).

Ms. Vizman has a B.Sc. in chemical and biotechnological engineering from Ariel University.

Asher Tal

Prof. Asher Tal

VP Clinical Development

Prof. Asher Tal founded and has previously been the head of the Pediatric Pulmonary Unit at Soroka Medical Center. During the past 15 years, he has also been the physician in charge of Soroka’s Pediatric Sleep Center. Soroka is affiliated with the Faculty of Health Sciences of Ben-Gurion University of the Negev.

Prof. Tal’s research interests include childhood asthma, bronchiolitis and wheezing in infancy, sleep-disordered breathing, pediatric and adult obstructive sleep apnea syndrome, and insomnia.

Prof. Tal has authored or co-authored more than 100 publications and is a member of the editorial board of Pediatric Pulmonology. Since 2008, Dr. Tal has chaired the Israeli Association of Pediatric Pulmonology.